Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 3, pp 339–343 | Cite as

Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan

  • Maria Sacramento Diaz-CarrascoEmail author
  • Raquel Olmos
  • Miguel Blanquer
  • Javier Velasco
  • Andrés Sánchez-Salinas
  • José María Moraleda
Short Research Report

Abstract

Background Due to their favorable toxicity profile and lack of interactions, benzodiazepines have been proposed as prophylaxis of busulfan induced seizures. Although they are broadly used in pediatric patients, the experience in adults is limited. Objective To describe the effectivity for seizure prophylaxis of the fixed 1 mg every 8 h (q8h) i.v. clonazepam dosing in adult patients receiving high dose i.v busulfan, as part of the hematopoietic progenitors transplant conditioning regimen. Methods Retrospective, observational study, from January 2008 to June 2012. Patients over 15 years old that had received high dose busulfan and prophylaxis with 1 mg q8h i.v. clonazepam from 12 h before the first dose of busulfan to 24 h after the last one were selected. The primary endpoint was the occurrence of seizures until 72 h after finishing conditioning. Results Thirty-three patients, 13 female and 20 male, median age 48, were included. Autologous transplant was performed in 17 patients and allogeneic in 16. Busulfan dose was 3.2 mg/kg every 24 h with a variable duration of 2–4 days. No seizures were recorded. Conclusion The 1 mg q8h i.v. clonazepam fixed schedule is easily administered and is effective for the prevention of high dose busulfan induced seizures in adult patients.

Keywords

Busulfan Clonazepam Hematopoietic stem cell transplantation HSCT Seizure prophylaxis 

Notes

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008;28(12):1502–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50(19):6203–7.PubMedGoogle Scholar
  3. 3.
    De la Camara R, Tomas JF, Figuera A, Berberana M, Fernandez-Rañada JM. High dose busulfan and seizures. Bone Marrow Transplant. 1991;7(5):363–4.Google Scholar
  4. 4.
    Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002;29(12):963–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood. 1994;84(7):2357–62.PubMedGoogle Scholar
  6. 6.
    Caselli D, Ziino O, Bartoli A, Santangelo G, Vanadia F, Aricò M. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant. 2008;42(2):135–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Meloni G, Nasta L, Pinto RM, Spalice A, Raucci U, Iannetti P. Clonazepam prophylaxis and busulfan-related myoclonic epilepsy in autografted acute leukemia patients. Haematologica. 1995;80(6):532–4.PubMedGoogle Scholar
  8. 8.
    Hamidieh AA, Hamedani R, Hadjibabaie M, Amini M, Sadrai S, Ghavamzadeh A. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell trasplantation: a prospective study. Pediatr Hematol Oncol. 2010;27(7):529–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Carreras E, Cahn JY, Puozzo C, Kröger N, Sanz G, Buzyn A, et al. Influence on busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30(7):2977–84.PubMedGoogle Scholar
  10. 10.
    Schwarer AP, Opat SS, Watson AL, Cole-Sinclair MF. Clobazam for seizure prophylaxis during busulfan chemotherapy. Lancet. 1995;346(8984):1238.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Maria Sacramento Diaz-Carrasco
    • 1
    Email author
  • Raquel Olmos
    • 1
  • Miguel Blanquer
    • 2
  • Javier Velasco
    • 1
  • Andrés Sánchez-Salinas
    • 2
  • José María Moraleda
    • 2
  1. 1.Hospital Pharmacy DepartmentVirgen de la Arrixaca HospitalMurciaSpain
  2. 2.Hematology DepartmentVirgen de la Arrixaca HospitalMurciaSpain

Personalised recommendations